Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bireociclib + AI in HR+/HER2- Advanced Breast Cancer
NCT05257395Phase 3Active, not recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing XZP-3287 + Letrozole/Anastrozole with Placebo + Letrozole/Anastrozole (2 arms). Primary endpoint: Investigator-assessed Progression-Free Survival at 24 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
bireociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05257395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257395.